Therapeutic targets for cancer: current concepts with PI 3-K, Akt, & mTOR.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

10 citing papers in PubMed.

1. DNA Damage Inducible Transcript 4 Gene: The Switch of the Metabolism as Potential Target in Cancer.Frontiers in oncology · 2018
   Review
2. Targeting molecules to medicine with mTOR, autophagy and neurodegenerative disorders.British journal of clinical pharmacology · 2016
   Review
3. Novel nervous and multi-system regenerative therapeutic strategies for diabetes mellitus with mTOR.Neural regeneration research · 2016
   Review
4. Regeneration in the nervous system with erythropoietin.Frontiers in bioscience (Landmark edition) · 2016
   Review
5. Erythropoietin and mTOR: A "One-Two Punch" for Aging-Related Disorders Accompanied by Enhanced Life Expectancy.Current neurovascular research · 2016
   Review
6. SIRT1 and stem cells: In the forefront with cardiovascular disease, neurodegeneration and cancer.World journal of stem cells · 2015
   Article
7. Programming apoptosis and autophagy with novel approaches for diabetes mellitus.Current neurovascular research · 2015
   Review
8. Taking aim at Alzheimer's disease through the mammalian target of rapamycin.Annals of medicine · 2014
   Review
9. Cutting through the complexities of mTOR for the treatment of stroke.Current neurovascular research · 2014
   Review
10. WISP1: Clinical insights for a proliferative and restorative member of the CCN family.Current neurovascular research · 2014
    Review

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as